Nautilus Biotechnology, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Nautilus Biotechnology, Inc. (NAUT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $2.37 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-07-28
- Nautilus Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $2.36, a 91.87% increase year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.23, a 54.78% decline year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $2.72, a 33.99% increase year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.03, a 47.00% decline year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.01, a 62.31% decline from fiscal 2024.
- Nautilus Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.68, a 10.74% increase from fiscal 2023.
- Nautilus Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $2.42, a 32.59% decline from fiscal 2022.
- Nautilus Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $3.59, a 60.42% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.37 10-Q · filed 2026-07-28 | |||
| 2026-03-31 | $2.36 10-Q · filed 2026-04-28 | |||
| 2025-12-31 | $1.01 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $0.99 10-Q · filed 2025-10-28 | |||
| 2025-06-30 | $0.99 10-Q · filed 2025-07-31 | |||
| 2025-03-31 | $1.23 10-Q · filed 2025-04-29 | |||
| 2024-12-31 | $2.68 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $2.68 10-Q · filed 2024-10-29 | |||
| 2024-06-30 | $2.65 10-Q · filed 2024-07-30 | |||
| 2024-03-31 | $2.72 10-Q · filed 2024-04-30 | |||
| 2023-12-31 | $2.42 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $2.37 10-Q · filed 2023-10-31 | |||
| 2023-06-30 | $2.34 10-Q · filed 2023-08-02 | |||
| 2023-03-31 | $2.03 10-Q · filed 2023-05-02 | |||
| 2022-12-31 | $3.59 10-K · filed 2023-02-23 | |||
| 2022-09-30 | $3.68 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | $3.81 10-Q · filed 2022-08-02 | |||
| 2022-03-31 | $3.83 10-Q · filed 2022-05-03 | |||
| 2021-12-31 | $9.07 10-K · filed 2022-02-24 | |||
| 2021-09-30 | $9.58 10-Q · filed 2021-11-02 | |||
| 2021-06-30 | $9.92 10-Q · filed 2021-08-10 | |||
| 2020-12-31 | $1.04 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |